Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.45 |
| ▸ | PER2 | O15055 | 6/20 | 0.37 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.37 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 2/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.35 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.34 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9892974 | 0.80 | L3MBTL1 (0.53) | CCNA2CDK2CCNA1ABL1L3MBTL1 | |
| SCHEMBL9893010 | 0.79 | CCNA2 (0.46) | CCNA2CDK2CCNA1PER2ABL1 | |
| SCHEMBL13626387 | 0.78 | DHODH (0.47) | CCNA2CDK2CCNA1PER2PTGER2 | |
| SCHEMBL13626388 | 0.77 | PTGER2 (0.52) | CCNA2CDK2CCNA1PTGER2PTGER3 | |
| SCHEMBL12112294 | 0.77 | PTGER2 (0.52) | CCNA2CDK2CCNA1PTGER2PTGER3 | |
| SCHEMBL6788699 | 0.77 | CCNA2 (0.55) | CCNA2CDK2CCNA1PTGER2CYP2C9 | |
| SCHEMBL11112763 | 0.77 | ESR1 (0.49) | CCNA2CDK2CCNA1PER2ABL1 | |
| SCHEMBL22352609 | 0.76 | PTGER2 (0.59) | CCNA2CDK2CCNA1PTGER2PTGER3 | |
| SCHEMBL13626386 | 0.76 | PTGER2 (0.59) | CCNA2CDK2CCNA1PTGER2PTGER3 | |
| SCHEMBL4636834 | 0.75 | GAA (0.46) | CCNA2CDK2CCNA1ABL1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286787-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286787-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | GLA, GUSB, GANAB | CCNA2 1927/4885CDK2 3449/4885CCNA1 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.